Clinical Trials Logo

Anti-PD1 Antibody clinical trials

View clinical trials related to Anti-PD1 Antibody.

Filter by:
  • None
  • Page 1

NCT ID: NCT04627012 Completed - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Start date: January 1, 2018
Phase:
Study type: Observational

For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC. This study will create a database that will provide clinical parameters and outcomes of patients undergoing Lenvatinib and anti-PD1 antibody as part of their standard of care in hopes of answering key clinical questions.